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ABSTRACT
Translation of the hepatitis C virus (HCV) RNA is
mediated by the interaction of ribosomes and
cellular proteins with an internal ribosome entry site
(IRES) located within the 5¢-untranslated region
(5¢-UTR). We have investigated whether small RNA
molecules corresponding to the different stem±loop
(SL) domains of the HCV IRES, when introduced
in trans, can bind to the cellular proteins and antag-
onize their binding to the viral IRES, thereby inhibit-
ing HCV IRES-mediated translation. We have found
that a RNA molecule corresponding to SL III could
ef®ciently inhibit HCV IRES-mediated translation in
a dose-dependent manner without affecting cap-
dependent translation. The SL III RNA was found to
bind to most of the cellular proteins which inter-
acted with the HCV 5¢-UTR. A smaller RNA corres-
ponding to SL e+f of domain III also strongly and
selectively inhibited HCV IRES-mediated translation.
This RNA molecule interacted with the ribosomal S5
protein and prevented the recruitment of the 40S
ribosomal subunit. This study reveals valuable
insights into the role of the SL structures of the HCV
IRES in mediating ribosome entry. Finally, these
results provide a basis for developing anti-HCV
therapy using small RNA molecules mimicking the
SL structures of the 5¢-UTR to speci®cally block
viral RNA translation.
INTRODUCTION
Hepatitis C virus (HCV) is a major human pathogen with an
estimated 170 million chronic carriers throughout the world,
many of whom are at a signi®cant risk for developing liver
cirrhosis and hepatocellular carcinoma (1). Current thera-
peutic strategies using interferon-a, either alone or in
combination with ribavirin, have poor ef®cacy (2).
Moreover, an important lesson obtained from the therapy of
other viral infections is that multiple drug targets are required
to prevent the emergence of drug-resistant varieties of the
virus (3).
HCV is a positive stranded RNA virus and translation of the
viral genomic RNA is an early obligatory step of the infection
process. Translation initiation of the uncapped viral RNA
takes place through the internal ribosome entry site (IRES)
located in the 5¢-untranslated region (5¢-UTR) (4). Translation
initiation from the IRES is mediated by a number of cellular
trans-acting factors like the La autoantigen (5) and poly-
pyrimidine tract-binding protein (PTB) (6), together with
some canonical eukaryotic initiation factors (eIFs), like eIF3
(7), eIF2 and eIF2B (8). It has been suggested that the IRES
acts as a structural scaffold with speci®cally placed recogni-
tion sites for recruiting the translation machinery (9). As this
mechanism of translation initiation is distinct from the cellular
cap-dependent mechanism, it is an attractive target for
antiviral therapeutics with high target speci®city and low
host cytotoxicity (10).
The concept of using RNA molecules as therapeutic agents
has aroused increasing interest in the past decade. Antisense
RNAs and trans-cleaving ribozymes have been studied as
potential inhibitors of HCV translation (11,12). Recently,
RNA interference using small interfering RNAs has proved to
be highly ef®cient in inhibiting the replication of a number of
viruses, including HCV (3).
Another strategy for blocking the replication of RNA
viruses has been to overexpress small and structured viral
RNA elements in target cells. These RNAs bind to viral
regulatory proteins and prevent their binding to corresponding
sequences in the viral RNA, thus inhibiting viral gene
expression. Overexpression of human immunode®ciency
virus (HIV) trans-activation response region (TAR) and Rev
response element (RRE) RNAs in CD4+ T cells prevented the
binding of viral Tat and Rev proteins to the viral RNA and
made the cells resistant to HIV replication (13,14). Also, a
60 nt RNA termed IRNA, isolated from Saccharomyces
cerevisae, has been shown to block IRES-mediated translation
of poliovirus and HCV by sequestering cellular trans-acting
factors which interact with the viral IRESs (15,16). La and
PTB-speci®c SELEX RNA have also been shown to inhibit
HCV IRES-mediated translation (17,18).
In this study we demonstrate a novel approach to inhibit
HCV IRES-mediated translation using small RNA molecules
mimicking the structure of the de®ned stem±loop (SL)
domains of the HCV IRES. We show that a small RNA
molecule corresponding to domain III of the HCV IRES and a
smaller molecule corresponding to the SL III e+f subdomain
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binds to speci®c cellular proteins interacting with the HCV
IRES and strongly inhibit HCV IRES-mediated translation
without inhibiting cap-dependent translation.
MATERIALS AND METHODS
Cells and plasmids
HeLa S3 and Huh7 cells were grown in DMEM (Invitrogen,
Carlsbad, CA) supplemented with 10% fetal bovine serum.
IRES domains II (nucleotides 18±123), III excluding III e and
f (nucleotides 121±290) and IV including 42 nt from the
coding region (nucleotides 291±383) were PCR ampli®ed
from the type 1b HCV 5¢-UTR (plasmid pCV, a gift from
Dr A. Nomoto, Tokyo University, Japan) and cloned in the
vector pCDNA3 (Invitrogen) to generate the plasmids pCD-
SL II, SL III and SL IV, respectively. The bicistronic vector
pRL-HCV1b having a Rluc (Renilla luciferase)±HCV 5¢-
UTR±Fluc (®re¯y luciferase) construct under control of the T7
promoter was a gift from Dr Richard Elliot (Glasgow
University, UK). The plasmid pRL-CMV (Promega,
Madison, WI) had a Rluc gene under control of the CMV
promoter. pCD-HCV-Fluc was constructed by cloning the
HCV 5¢-UTR (nucleotides 18±383) upstream of the Fluc gene
in pCDNA3. The encephalomyocarditis virus (EMCV)
bicistronic plasmid was constructed by inserting the EMCV
functional IRES, PCR ampli®ed from the vector pCITE
(Novagen, Darmstadt, Germany), between Fluc and green
¯uorescent protein (GFP) genes cloned in the vector
pCDNA3. The HCV subgenomic replicon (BB7) was a gift
from Apath Inc. (St Louis, MO).
In vitro transcription
The plasmid pRL-HCV1b was linearized downstream of Fluc
and transcribed using T7 RNA polymerase in the presence of
RNA Cap Analog (Invitrogen) to generate the bicistronic
capped RNA. The plasmids pCD-SL II, SLIII and SL IV were
linearized with EcoRI and transcribed by in vitro run-off
transcription reactions under standard conditions using
reagents from Promega. 32P-labeled HCV 5¢-UTR RNA and
the SL RNAs were transcribed from respective plasmids using
T7 RNA polymerase and [a-32P]UTP (Perkin Elmer Life
Sciences, Boston, MA).
Oligonucleotide-driven transcription
Synthetic DNA oligonucleotides corresponding to domain III
SL a+c, b, d and e+f structures (sequences: a+c, CGCCTT-
GGCCACTCATGTGGCCTTAACTCTAAACCCGCACGG-
GGGCG; b, GGTCCTG CTGGCCCAGGAAAGAACCTA-
GTTGGGCGAGTTACGGACC; d, ATCGGCTCATCACA
ACCCAGCGCTTTCGGAACA; e+f, GGGAGGGCCCTCT-
CGGTAGAACACCATGACGGACTATCCCACGAACGC-
TCACGGGGCCCTCC) with T7 promoter sequences at the 5¢
end were obtained from Sigma Aldrich (St Louis, MO). The
SL III e+f (A297G) oligo had the same sequence as the SL III
e+f oligo except for replacement of a T residue by a C at
position 37. These oligonucleotides were annealed to T7 RNA
polymerase promoter primers and transcribed in vitro using T7
RNA polymerase as described earlier (15). Radioactively
labeled RNAs were transcribed using the same templates and
[a-32P]UTP.
In vitro translation
In vitro translation was carried out using 1 mg of template
RNA in 17 ml of micrococcal nuclease-treated rabbit
reticulocyte lysate (RRL) medium (Promega) and either
0.5 ml each of amino acid mixtures minus methionine and
minus cysteine or 20 mCi of [35S]methionine (Perkin Elmer).
The reaction mixtures were preincubated with in vitro tran-
scribed small RNAs as indicated in Results. After adding
template RNA, the reaction mixtures were incubated at 30°C
for 90 min and the products were analyzed either using a Dual
Luciferase assay system (Promega) in a TD 20/20
Luminometer (Turner Designs, Sunnyvale, CA) or resolved
on SDS±12.5% polyacrylamide gels followed by phosphor-
imaging (Fuji Imaging, Japan).
Puri®cation of S5 ribosomal protein
Escherichia coli JM109 cells were transformed with the
plasmid pQE-S5 (a gift from Dr S. Fukushi, Biomedical
Laboratories, Japan) expressing the poly(His)-tagged S5
protein. Protein expression in bacterial culture was induced
by 0.8 mM IPTG and puri®ed using Ni2+±nitrilotriacetic acid±
agarose (Qiagen, Hilden, Germany) under non-denaturing
conditions and eluted with 100 mM imidazole.
UV-induced crosslinking of proteins with RNA
The in vitro transcribed 32P-labeled RNAs were incubated
with HeLa S10 extract or puri®ed protein in 23 RNA binding
buffer and UV-crosslinked as described earlier (19). Unbound
RNAs were digested by treatment with 30 mg of RNase A at
37°C for 30 min. The protein±nucleotidyl complexes were
electrophoresed on SDS±10% polyacrylamide gels followed
by autoradiography.
DNA and RNA transfection
Monolayers (60±70% con¯uent) of HeLa and Huh7 cells in 35
mm dishes were co-transfected with plasmid DNAs using Tfx
20 reagent (Promega) as indicated in Results. The cells were
harvested 48 h after transfection and luciferase activity was
assayed. Huh7 cells were co-transfected with in vitro tran-
scribed RNAs using Tfx 20 reagent as indicated in Results.
The cells were harvested 16 h after transfection and luciferase
activity was assayed. DNA and RNA quantities were normal-
ized using pGEM 3Z DNA (Promega) or an in vitro
transcribed RNA corresponding to its polylinker sequence.
Huh7 cells were transfected with the BB7 HCV subgenomic
replicon RNA followed by retransfection with SL III e+f RNA
after 16 h. The cells were harvested 24 h after transfection
with SL III e+f and the total RNA was isolated using Tri
Reagent (Sigma Aldrich).
RNase protection assay
Equal quantities of total RNA from Huh7 cells co-transfected
with the HCV replicon RNA and SL III e+f RNA were alcohol
precipitated and resuspended in 30 ml of hybridization buffer
(80% deionized formamide, 40 mM PIPES, pH 6.4, 400 mM
NaCl and 1 mM EDTA) containing 105 c.p.m. HCV 5¢-UTR
positive sense RNA probe and incubated at 95°C for 10 min,
followed by 55°C for 18 h. An aliquot of 300 ml of RNase
digestion buffer (300 mM NaCl, 10 mM Tris±HCl, pH 7.4,
5 mM EDTA, 10 U RNase T1 and 40 mg/ml RNase A) was
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added to each reaction with incubation at 30°C for 1 h,
followed by 20 ml of 10% SDS and 10 ml of 10 mg/ml
proteinase K and incubation at 37°C for 30 min. The RNA was
alcohol precipitated, resuspended in formamide loading buffer
and resolved by 10% urea±PAGE.
Ribosomal assembly assay
32P-labeled HCV 5¢-UTR RNA (~105 c.p.m.) was added to
25 ml of translation reaction containing 17.5 ml RRL, in the
presence or absence of a 200-fold excess of SL III e+f RNA.
An aliquot of 2 mM 5¢-Guanylyl imidophosphate (GMP-PNP)
(Sigma Aldrich) was added to the reaction as indicated in the
results. The reactions were incubated at 30°C for 15 min,
diluted to 150 ml with gradient buffer (20 mM Tris±HCl,
pH 7.5, 100 mM KCl, 3 mM MgCl2, 1 mM DTT) and overlaid
on a 5±30% linear sucrose gradient. The ribosomal complexes
were sedimented by ultracentrifugation for 3 h at 4°C and
30000 r.p.m. Fractions (500 ml) were collected from the
bottom of the column and the radioactivity was measured in a
liquid scintillation counter.
Statistical analysis
The means 6 SD of ®ve independent in vitro translation
experiments are represented. Data from the co-transfection
experiments are expressed as means 6 SD of three independ-
ent replicates. The signi®cance of differences between means
was tested using Student's t-test. IC50 values for inhibitory
RNAs were determined by non-linear regression analysis of
the inhibition curves using SigmaPlot (SPSS Inc., Chicago,
IL).
RESULTS
Speci®c inhibition of HCV IRES-mediated translation by
RNA corresponding to SL III of the HCV 5¢-UTR
RNAs corresponding to the three major domains of the HCV
5¢-UTR: SL II, SL III (excluding SL III e+f) and SL IV
(including SL III e+f) (Fig. 1A) were transcribed in vitro. 100-
and 200-fold molar excesses of these RNAs were exogenously
added to in vitro translation reactions of the Rluc±HCV±Fluc
bicistronic RNA and the reporter gene products were
radiolabeled (Fig. 1B). The three RNA molecules differen-
tially inhibited HCV IRES-mediated translation of Fluc and
cap-dependent translation of Rluc in a dose-dependent man-
ner. SL II moderately inhibited HCV IRES-mediated and cap-
dependent translation whereas SL IV was found to strongly
inhibit both. On the other hand, SL III RNA was found to
strongly inhibit HCV IRES-mediated translation with a
marginal effect on cap-dependent translation (Fig. 1B).
Similar results were obtained when the luciferase activity
from non-radiolabeled reporter gene products was assayed
(Fig. 1C). SL III RNA caused a maximum 80% reduction in
Fluc activity whereas there was 73 and 57% inhibition at
corresponding doses of SL IV and SL II, respectively (Fig. 1C).
IC50 values for SL III, IV and II were determined to be,
respectively, 35-, 60- and 152-fold excesses of the template
RNA. There was no signi®cant inhibition of Rluc activity by
either SL III or SL II, whereas SL IV caused 68% inhibition at
200-fold excess concentration (Fig. 1D). These observations
indicate both an ef®cient and selective inhibition of HCV
IRES-mediated translation by SL III which was signi®cantly
higher than that caused by SL II or SL IV RNA (P < 0.01). SL
IV caused a strong inhibition of both HCV IRES-mediated
translation and cap-dependent translation whereas the effect of
SL II on either was not pronounced.
SL III RNA binds to a majority of cellular proteins
which interact with the HCV 5¢-UTR
The inhibitory effect of SL III RNA was hypothesized to be
due to its ability to bind to cellular proteins that interact with
the HCV IRES. We investigated the protein binding pro®les of
SL II, III and IV RNAs with HeLa cytoplasmic extract as
HeLa cells support ef®cient HCV IRES activity and compared
it with that of the full-length HCV 5¢-UTR. SL II, III and IV
were found to have distinct protein-binding pro®les and SL III
was found to bind to a majority of cellular proteins which
interacted with the HCV 5¢-UTR (Fig. 2A). Competition
experiments using excess unlabeled RNAs demonstrated that
SL III and IV RNAs competed out the interaction of speci®c
proteins with the HCV 5¢-UTR (data not shown). These
observations showed that SL III RNA could bind to the
majority of proteins that interacted with the HCV IRES and
could therefore antagonize their interaction with the full-
length 5¢-UTR.
Speci®c inhibition of HCV IRES-mediated translation
in vivo by SL III RNA
To investigate the inhibitory activity of the SL III RNA in vivo,
three-way co-transfections were performed in HeLa cells
using pRL-CMV, pCD-HCV-Fluc and two different concen-
trations of pCD-SL III and pCD-SL II DNAs. SL II, which had
not signi®cantly inhibited IRES-mediated or cap-dependent
translation in vitro, was utilized as the negative control. SL III
signi®cantly reduced (P < 0.01) HCV IRES activity from the
control at both concentrations (74 and 85% inhibition,
respectively) whereas there was no signi®cant effect on cap-
dependent translation (Fig. 2B). SL II did not signi®cantly
inhibit either cap-dependent or IRES-mediated translation
compared to the control. The co-transfections were repeated in
Huh7 cells, a human hepatocellular carcinoma cell line
supporting ef®cient HCV replication (20). There was a
signi®cant reduction (P < 0.01) in HCV IRES-mediated
translation from the control by SL III although the extent of
inhibition was less (37 and 68% inhibition at the two
concentrations) than that observed in HeLa cells using similar
quantities of transfected DNA (Fig. 2C). These data demon-
strate that SL III RNA could selectively inhibit HCV IRES-
mediated translation in both non-liver-derived (HeLa) and
liver-derived (Huh7) cells.
Inhibition of HCV IRES-mediated translation by an
RNA corresponding to SL III e+f
As we observed the maximum translation inhibitory effect
with RNA molecules corresponding to domain III of the HCV
IRES, we tried to generate smaller RNAs corresponding to its
speci®c subdomains that would retain the ability to inhibit
HCV IRES-mediated translation. For this purpose, small
RNAs corresponding to the SL III a+c, b, d and e+f
subdomains (Fig. 3A) were generated by oligonucleotide-
driven transcription. Increasing concentrations of these RNAs
were exogenously added to in vitro translation reactions of the
1680 Nucleic Acids Research, 2004, Vol. 32, No. 5
HCV bicistronic RNA. Interestingly, SL III e+f RNA caused a
very strong inhibition (89% reduction from control) of HCV
IRES-mediated translation (Fig. 3B) with no signi®cant effect
on cap-dependent translation (Fig. 3C). SL III b caused 57%
inhibition of HCV IRES-mediated translation but this was
accompanied by a 53% decrease in cap-dependent translation
(Fig. 3B and C). SL III a+c and III d RNAs showed minor
reductions in the ef®ciency of HCV IRES-mediated transla-
tion. The IC50 of SL III e+f RNA was calculated to be a
15-fold molar excess of template RNA. These observations
demonstrated that the small RNA corresponding to the SL III
e+f subdomain could strongly inhibit HCV IRES-mediated
translation in vitro without signi®cantly inhibiting cap-
dependent translation.
Effect of SL III e+f RNA on HCV IRES-mediated
translation and replication in vivo
As SL III e+f RNA showed a strong inhibition of HCV IRES-
mediated translation in vitro, we next investigated its effect on
HCV translation in vivo. Huh7 cells were co-transfected with
in vitro transcribed HCV bicistronic RNA together with two
concentrations of SL III e+f RNA. SL III d, which had not
Figure 1. Speci®c dose-dependent inhibition of HCV IRES-mediated translation in vitro by HCV SL III RNA. (A) Proposed secondary structure of the HCV
IRES RNA spanning nucleotides 40±372 of the 5¢-UTR of the viral RNA (adapted from 41). The domains that were PCR ampli®ed and cloned to generate
small RNAs are delineated. (B) 100- and 200-fold molar excesses of in vitro transcribed SL II, III and IV RNAs were added to in vitro translation reactions
of HCV bicistronic RNA. An aliquot of 5 ml of the translation reactions was resolved by SDS±12.5% PAGE and exposed for phosphoimaging. The Fluc and
Rluc protein products are indicated by arrows. (C) The percent Fluc activity, representing the ef®ciency of HCV IRES-mediated translation from a HCV bicis-
tronic template, in the presence of six increasing concentrations of SL II, III and IV RNAs was plotted. The Fluc activity at each concentration is represented
as a percentage of the control reaction (expressed as 100%). The data were ®tted to a non-linear regression curve to determine IC50 values. (D) The percent
Rluc activity, representing the ef®ciency of cap-dependent translation from the same set of experiments, was plotted. The Rluc activity at each concentration
is represented as a percentage of the control reaction. The translation ef®ciency was not reduced to below 50% by either SL III or SL II.
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shown a signi®cant effect, was used as the negative control.
SL III e+f RNA signi®cantly inhibited (P < 0.01) HCV IRES-
mediated translation in a dose-dependent manner (45 and 85%
inhibition at the two concentrations) with no signi®cant
inhibition of cap-dependent translation (Fig. 4A). Addition of
SL III d RNA did not cause any inhibition of either IRES-
mediated or cap-dependent translation (Fig. 4A).
As SL III e+f RNA inhibited HCV IRES-mediated trans-
lation in Huh7 cells, we also tried to determine its effect, if
any, on HCV replication from a HCV subgenomic replicon.
Therefore, the BB7 HCV replicon (21) RNA was transfected
into Huh7 cells followed by transfection with two concentra-
tions of SL III e+f RNA corresponding to the amounts used for
inhibition of translation from the bicistronic RNA. In a control
experiment in which the SL III RNA was co-transfected with
the replicon RNA into Huh7 cells, a RNase protection assay
using a HCV 5¢-UTR antisense probe demonstrated the
presence of both the input replicon RNA and the SL III
RNA 48 h after transfection (data not shown). A RNase
protection assay using a HCV 5¢-UTR positive sense RNA
probe to assay for RNA replication demonstrated only a
marginal reduction in HCV replication by SL III e+f RNA at
the concentrations of RNA used (Fig. 4B). This suggested that
the inhibitory activity of SL III e+f RNA was speci®c to HCV
IRES-mediated translation rather than replication of the HCV
RNA. This also suggested that there was possibly no effect of
SL III e+f RNA on EMCV IRES activity, as protein synthesis
from the HCV replicon was under the translational control of
the EMCV IRES. In order to investigate this possibility, 100-
and 200-fold molar excesses of SL III e+f RNA were added to
in vitro translation reactions of an EMCV bicistronic RNA,
but no effect on EMCV-IRES-mediated translation of the GFP
reporter gene was observed (Fig. 4C). This also suggested that
the SL III e+f RNA speci®cally inhibited HCV IRES-
mediated and not the picornaviral IRES-mediated translation.
Binding of cellular proteins to the small RNAs
corresponding to SL III subdomains: speci®c interaction
of the S5 ribosomal protein with SL III e+f RNA
As SL III e+f RNA was found to strongly inhibit HCV IRES-
mediated translation in vitro and in vivo, we investigated the
protein-binding pro®le of the RNA to correlate it with the
translation inhibitory activity. The SL III subdomain RNAs
demonstrated differential binding to speci®c proteins that
interacted with the HCV domain III RNA (Fig. 5A). A 25 kDa
protein was found to interact strongly with SL III e+f RNA but
did not interact with the other RNAs. This protein may
correspond to the S5 ribosomal protein, as a single mutation in
SL III e (A297G) of the HCV 5¢-UTR has been shown to
abrogate binding of this protein (22). In order to investigate
this possibility, bacterially expressed S5 ribosomal protein
was used in a UV-crosslinking assay. SL III e+f RNA strongly
interacted with the puri®ed protein whereas SL III d, which
had not shown any interaction with p25 from HeLa cells,
failed to do so (Fig. 5B). The full-length HCV 5¢-UTR also
interacted with the S5 protein, but to a lesser extent than SL III
e+f (Fig. 5B). Therefore, the small RNAs corresponding to the
subdomains of domain III could bind to a number of cellular
proteins which interacted with the HCV IRES and SL III e+f
uniquely interacted with the S5 ribosomal protein. An in vitro
transcribed mutant SL III e+f RNA harboring the A297G
mutation in SL III e showed a drastic reduction in binding to
the p25 protein from HeLa cytoplasmic extract (Fig. 6A) and
also puri®ed S5 protein (Fig. 6B). 100- and 200-fold molar
excesses of this mutant SL III e+f RNA also failed to inhibit
HCV IRES-mediated translation in vitro (Fig. 6C). These
observations suggested that the SL III e+f RNA inhibited HCV
IRES-mediated translation speci®cally by binding to S5
ribosomal protein.
SL III e+f RNA prevented the assembly of ribosomal
complexes on the HCV IRES
Binding of the 25 kDa S5 ribosomal protein has been
suggested to be crucial for ef®cient translation mediated by
the HCV IRES (23). As SL III e+f RNA was found to interact
strongly with the S5 protein, we investigated its effect on
ribosome recruitment by the HCV IRES. For this purpose,
ribosomal assembly reactions containing radiolabeled HCV
5¢-UTR were incubated with a 200-fold molar excess of SL III
e+f RNA and analyzed by sucrose density gradient ultracen-
trifugation. In the absence of SL III e+f RNA, HCV IRES
showed the formation of both 48S and 80S ribosomal
complexes (Fig. 7A). However, in the presence of SL III e+f
RNA, formation of both of these complexes was signi®cantly
reduced (Fig. 7A), suggesting that SL III e+f prevented the
Figure 2. Interaction of HCV 5¢-UTR SL RNAs with HeLa cytoplasmic
proteins and effect of SL III on HCV IRES-mediated translation in vivo. (A)
32P-labeled RNAs corresponding to the full-length HCV 5¢-UTR and SL II,
III and IV domains were UV-crosslinked to HeLa S10 cytoplasmic extract,
digested with RNase A and resolved by SDS±10% PAGE. M represents
14C-labeled protein molecular weight markers. (B) Three-way co-transfec-
tions were performed in HeLa cells using pRL-CMV, pCD-HCV5¢-UTR-
Fluc and two concentrations of pCD-SL III and pCD-SL II DNAs. DNA
quantity per dish was normalized by transfecting pGEM-3Z DNA. The
black bars represent Fluc activity (HCV IRES-mediated translation) whereas
the gray bars represent Rluc activity (cap-dependent translation). (C) The
same experiment was repeated in the Huh7 cell line. Combined data from
three independent experiments in each cell line are shown. Luciferase activ-
ity in control reactions is expressed as 100%. Values which signi®cantly dif-
fer from controls (P < 0.01) are indicated by asterisks.
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assembly of ribosomal complexes on the HCV IRES. To
further elucidate the role of SL III e+f RNA, the ribosomal
assembly reactions were incubated with GMP-PNP, which
inhibits translation initiation at the 48S stage by preventing the
release of eIF2. Addition of GMP-PNP abolished the 80S peak
in the control reaction, demonstrating that only the 48S
complex was being assembled (Fig. 7B). In the presence of SL
III e+f the 48S complex formation was also abrogated,
suggesting that SL III e+f prevented binding of the 40S
ribosomal subunit to the HCV IRES (Fig. 7B). This supported
the earlier observation that SL III e+f interacted with the S5
ribosomal protein, a component of the 40S subunit. Taken
together, these observations suggest that the SL III e+f RNA
inhibited HCV IRES-mediated translation by interacting with
a component of the 40S ribosomal subunit and thereby
prevented ribosomal assembly on the HCV IRES.
DISCUSSION
The process of IRES-mediated translation is an attractive
target for antiviral drug design (24). Selective inhibition of the
HCV IRES-mediated mechanism by the SL III e+f RNA of the
HCV 5¢-UTR has a potential to be used as a therapeutic
strategy with many associated advantages. Firstly, as the
Figure 3. Speci®c inhibition of HCV IRES-mediated translation in vitro by HCV 5¢-UTR SL III e+f RNA. (A) Proposed secondary structure of HCV IRES
(internal ribosome entry site) domain III (nucleotides 121±315), delineating the SL structures which were generated by oligonucleotide-
driven transcription. (B) The percent Fluc activity, representing the ef®ciency of HCV IRES-mediated translation from a HCV bicistronic template, in the
presence of ®ve increasing concentrations of SL III a+c, b, d and e+f RNAs was plotted. Luciferase activity in control reactions is expressed as 100%. The
data for SL III e+f was ®tted to a non-linear regression curve to determine the IC50 value. (C) The percent Rluc activity representing the ef®ciency of cap-
dependent translation from the same set of experiments was plotted. The reporter gene activity at each concentration is represented as a percentage of the con-
trol reaction.
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interactions between host cellular proteins and a highly
conserved region of the viral RNA is targeted, the chance of
generation of viral escape mutants is very low. Approaches
like siRNA treatment have demonstrated the rapid emergence
of escape mutants in poliovirus (25). Although the rate of
HCV replication is not as high as that of poliovirus (3), any
sequence-speci®c antiviral molecule would exert a selection
pressure for the generation of escape variants, unlike a strategy
targeting host protein±viral RNA interactions. Moreover, the
activity of the HCV IRES being highly structure dependent,
only mutational events that can alter the IRES structure would
allow the virus to circumvent inhibition by this approach.
Secondly, the RNA molecule being a part of the viral genome,
if administered prophylactically to patients harboring the viral
RNA it would not be expected to give rise to non-speci®c
immune responses as in the case of antisense RNAs (26).
Thirdly, as binding of the cellular proteins is probably
dependent on the RNA structure, stabler derivatives and
Figure 4. Effect of SL III e+f RNA on HCV IRES-mediated translation and
replication in vivo. (A) Huh7 cells were co-transfected with 6 mg of in vitro
transcribed capped HCV bicistronic RNA (schematically represented) and
two concentrations (6 and 12 mg) of either SL III e+f RNA or SL III d
RNA. The RNA quantities in each dish were normalized by adding
appropriate amounts of an in vitro transcribed RNA corresponding to the
polylinker sequence of the pGEM 3Z plasmid. The black bars represent
Fluc activity (HCV IRES-mediated translation) whereas the gray bars
represent Rluc activity (cap-dependent translation). Luciferase activity in
control reactions is expressed as 100%. Values which signi®cantly differ
from controls (P < 0.01) are indicated by asterisks. (B) Huh7 cells were
either mock transfected (lane 1) or transfected with 8 mg of BB7 HCV
replicon RNA (schematically represented). Twelve hours post-transfection
the cells were retransfected with two concentrations (6 and 12 mg) of SL III
e+f RNA (lanes 3 and 4). The cells were harvested 24 h after retransfection,
total RNA was isolated and a RNase protection assay was performed using
a [32P]UTP-labeled HCV 5¢-UTR positive sense probe. The RNAs were
resolved by 10% urea±PAGE. Lane M shows the migration of a
radiolabeled 100 bp DNA ladder. (C) 100- and 200-fold molar excesses of
in vitro transcribed SL III e+f RNA was added to in vitro translation
reactions of Fluc-EMCV-GFP bicistronic RNA in RRL. An aliquot of 10 ml
of the translation reactions was resolved by SDS±12.5% PAGE and exposed
for phosphorimaging. The 35S-labeled Fluc and GFP protein products are
indicated by arrows.
Figure 5. Binding of domain III stem±loop RNAs to HeLa cellular proteins
and interaction of SL III e+f RNA with the S5 ribosomal protein. (A) 32P-la-
beled RNAs corresponding to the HCV SL III a+c, b, d and e+f subdomains
were UV-crosslinked to HeLa S10 cytoplasmic extract, digested with RNase
A and resolved by SDS±10% PAGE. The position of p25 bound to SL III
e+f RNA is indicated by an arrow. (B) Puri®ed recombinant S5 ribosomal
protein was UV-crosslinked to HCV SL III e+f, SL III d and full-length
HCV 5¢-UTR RNA. The nucleoprotein complexes were resolved by
SDS±12% PAGE and the position of S5 protein (p25) is indicated.
Figure 6. SL III e+f (A297G) RNA fails to bind to S5 ribosomal protein
and does not inhibit HCV IRES-mediated translation. (A) 32P-labeled RNAs
corresponding to SL III e+f and SL III e+f (A297G) were UV-crosslinked
to HeLa S10 extract and digested with RNase A. The nucleoprotein
complexes were resolved by SDS±15% PAGE and the position of p25 is
indicated. (B) The same RNAs were UV-crosslinked to puri®ed S5
ribosomal protein and the nucleoprotein complexes were resolved by
SDS±15% PAGE. (C) 100- and 200-fold molar excesses of in vitro
transcribed SL III e+f (A297G) RNA was added to in vitro translation
reactions of HCV bicistronic RNA and luciferase activity was assayed. The
black bars represent Fluc activity (HCV IRES-mediated translation) whereas
the gray bars represent Rluc activity (cap-dependent translation). Luciferase
activity in control reactions is expressed as 100%. Combined data from
three independent experiments are represented.
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small molecule structural analogs of the RNA could be
utilized. We found that the amounts of SL III e+f RNA
required to inhibit HCV IRES-mediated translation was more
(IC50 » 0.6 mM) than the amount of antisense RNA targeted
against SL III d (IC50 < 10 nM) required for a similar
inhibition (27). However, the absolute values of RNA required
to inhibit translation from an HCV IRES-containing construct
by the two approaches cannot be compared as the amount of
competitor SL RNA required to inhibit translation is depend-
ent on the concentration of template RNA used as well as the
levels of trans-acting factors present that interact with the
IRES RNA.
The major domains of the HCV IRES that have been shown
to interact with cellular factors and the 40S ribosomal subunit
are SL III and SL IV (28,29). In our study, among the major
domains of the HCV IRES, SL III RNA strongly inhibited
HCV IRES-mediated translation and could ef®ciently bind to
most proteins that interacted with the HCV 5¢-UTR. The SL III
e+f RNA, which inhibited HCV IRES-mediated translation
even more ef®ciently, interacted with ribosomal protein S5
(30). Binding of this protein to the HCV IRES has been
suggested to be crucial for the ef®cient translation of HCV
RNA (23). A single mutation in SL III e (A297G), which
abrogated binding of this protein, has been found to abolish
HCV IRES activity (22,31). In our study, a SL III e+f RNA
containing this mutation failed to bind the S5 protein and was
also unable to inhibit HCV IRES-mediated translation.
However, direct binding of the 40S ribosomal subunit to the
HCV IRES involves SL III d, SL III e+f, the pseudoknot
region and SL IV (32). Our observations suggest that although
SL III e+f might not sequester the 40S ribosomal subunit
independently, it could prevent its interaction with the HCV
IRES by interacting with one of its component proteins. The
40S subunit S5 protein has not been found to interact with
eukaryotic mRNAs either in the 48S preinitiation complex or
in polysomes (33). This possibly explains why SL III e+f RNA
did not inhibit cap-dependent translation. However, the
prokaryotic homolog of S5 protein, S7, has been shown to
be present near the E site of the bacterial 30S ribosome subunit
and interacts with tRNA and mRNA (30,34). Therefore, the
HCV IRES, which has been suggested to have a prokaryotic-
like mode of interaction with the 40S ribosomal subunit (32),
may interact with S5 protein, although eukaryotic mRNAs and
picornaviral IRESs (35) have not been reported to interact
with this protein. The SL III RNA lacking SL III e+f also
failed to signi®cantly inhibit cap-dependent translation, prob-
ably due to its inability to bind ef®ciently to the 40S ribosomal
subunit. This suggests that only RNA that can constitute the
intact ribosome-binding site of the HCV IRES is able to recruit
40S subunits. Our strategy of using individual SLs from this
region prevented the sequestration of ribosomes and the
consequent inhibition of cap-dependent translation. On the
other hand, SL IV RNA inhibited both IRES-mediated and
cap-dependent translation, probably because it contained SL
III e+f and the pseudoknot region together with domain IV,
which generated the core ribosome-binding site (36). SL III b
inhibited both IRES-mediated and cap-dependent translation,
probably because of its strong interaction with eIF3 and PTB,
which interacts with this region of the HCV IRES (37,38).
However, the larger SL III RNA did not inhibit cap-dependent
translation probably because its different secondary structure
conferred a lower af®nity for binding to these proteins. SL II
RNA did not inhibit HCV translation by interacting with the
40S subunit, which is consistent with earlier reports that a
domain II-deleted IRES construct could bind the 40S subunit
with nearly wild-type af®nity (37).
The inhibitory effect of the small RNAs was not by RNAi as
replication of HCV RNA was not inhibited by SL III e+f RNA.
RNAi using siRNA against the HCV 5¢-UTR has been
demonstrated using the HCV replicon system (39). However,
Figure 7. SL III e+f prevents 40s ribosomal subunit recruitment by the
HCV IRES. (A) Sucrose gradient sedimentation pro®les of [32P]UTP-labeled
HCV 5¢-UTR RNA incubated in RRL in the absence and presence of a
200-fold excess of unlabeled SL III e+f RNA. (B) Sedimentation pro®le of
radiolabeled HCV 5¢-UTR RNA in the presence of 2 mM GMP-PNP in the
presence or absence of a 200-fold excess of unlabeled SL III e+f RNA. The
®lled circles represent the control reaction pro®le and the open circles show
the pro®le in the presence of SL III e+f. Both pro®les show the counts per
minute as a percentage of the total counts added to the reaction (~105
c.p.m.) against the fraction number of the gradient. The fractions were
collected from the bottom upwards. The 80S and 48S ribosomal peaks are
indicated.
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studying the inhibition of translation by the approach used in
our study might not be feasible using the replicon system as
the HCV replicons reported in the literature are under
translational control of the EMCV IRES and the SL III e+f
RNA did not inhibit EMCV IRES activity. Therefore, other
models, like mice containing chimeric mouse/human livers
supporting HCV infection and replication (40), may provide a
suitable system to test the ef®cacy of this strategy. With recent
advances in targeted gene delivery, this approach of select-
ively targeting HCV translation, in conjunction with siRNAs
targeting HCV replication, may provide a basis for developing
an effective anti-HCV therapy.
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